• Explore /
  • Poster
  • / GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non–small cell lung cancer (NSCLC)—A randomized, double-blind trial.

GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non–small cell lung cancer (NSCLC)—A randomized, double-blind trial.

Abstract Poster

Authors

null

François Ghiringhelli

University of Burgundy, Genetic and Immunotherapy Medical Institute, Centre Georges Francois Leclerc, Dijon, France

François Ghiringhelli , Ludovic Doucet , Patricia Barre , Eric Pichon , Santiago Ponce Aix , Oscar Juan-Vidal , Enric Carcereny , Tariq Sethi , Bertil Lindmark , Alison MacKinnon , Vassilios Aslanis , Zahir Rajiwate , Linda Basse

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT05240131

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS9152)

DOI

10.1200/JCO.2022.40.16_suppl.TPS9152

Abstract #

TPS9152

Poster Bd #

130b

Abstract Disclosures

Similar Posters

Poster

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.

First Author: Laurent Mhanna

First Author: Melissa Lynne Johnson

First Author: Samuel Rosner

First Author: Tony S. K. Mok